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Background:  Patients with peripheral vascular disease (PVD) carry a long term high mortality rate of 50%. Risk factor reduction of athersoclerosis 
is recommended by ACC/AHA guidelines to reduce the high mortality. However, the impact of guideline adherence of medication utilization on 
clinical outcomes is not known. We investigated the role of guideline driven risk factor reduction via medication on mortality at 30 days, 1 year and 
3 year in PVD patients.
Methods: At our institute, 303 patients who received either endovascular or surgical procedures for PVD treatment between from January 1, 2006 
and December 31, 2007 were retrospectively evaluated. The medications analyzed were aspirin, angiotensin converting enzyme inhibitor (ACE) or 
angiotensin receptor blocker (ARB) and statins. The Fisher exact test and Chi square were used for data analysis.
Results:  69 patients (22.8%) were receiving all three medications, with 109 patients (36.0%) receiving 2 medications, 88 patients (29.0%) taking 
only 1 medication and 37 patients (12.2%) were not taking any medication. Individual medication compliance was 191 (63.0%) patients were 
receiving aspirin, 176 patients were on a statin (58.1%) and 146 patients (48.2%) were taking either an ACE inhibitor or ARB. The mortality rates 
increased progressively at 30 days, one year and 3 years in patients not taking Aspirin, ACE/ARB or statins. As the compliance of the patient to use 
one or more of the medications increased there was a trend to reduce mortality at 30 days (chi square analysis p = 0.055). The mortality reduction 
showed a trend when the number of medications increased from zero to all three per the ACC guidelines.
Conclusions: Adherence to ACC guidelines to use Asprin, ACE/ARB and statins may reduce the long term mortality of PVD patients.
